Mid-year grades – 2020 What’s Hot, What’s Not

July 23, 2020

Every January, we at TTC haul out our crystal ball, test the market, examine all the trend reports, and then present our predictions for the coming year. Of course, by the time we get to that point, most experts have pontificated, editorial calendars have been printed and many prophecies, self-fulfilling and otherwise, emerge or crash and burn. At TTC, we try to get beyond the obvious; and sometimes deliberately seek literally, ‘the edge’.

In January, when we published our ‘What’s Hot and Not’ list, no one was even dimly aware of an important new factor that would change our lives, economies and health priorities. We made our bold prophecies against the prevailing micro and macro-trends; some have borne out, and many more appear to have dropped in both priority and urgency. 

On our ‘what’s hot’ list we documented prebiotics and synbiotics, mushroom products, and Mintel’s recently proclaimed darling of the nutra universe, collagen and nutribeauty. We were on point with all three of these. Prebiotic awareness and interest continue to grow, accelerated by the immune uptick earlier this year, and also part of a general wave of interest associated with another one of our hot areas – the microbiome. Plus, as companies brand extend from probiotics alone, we are seeing more interest in synbiotics. So, we’ll consider that a win. Mushrooms also benefited from the immune focus of recent months and articles like this Insider piece have helped raise their profile. On the nutribeauty and collagen front, perhaps nothing points out the future potential of this category more than the Nestle acquisition of Vital Proteins.

The combination of personalization and the microbiome is another one of those dynamic duos, and the first half of 2020 has seen a continued acceleration of microbiome research, as the microbiome gets implicated in more mechanisms associated with immunity and inflammation. We are starting to see the emergence of synbiotics and prebiotics intended to address population groups and type, so while not ‘n=1’ personalization, certainly a move towards targeted supplement delivery based on diagnostics and metabolomics.

Remember CBD? We said that we’d see advances in proving the safety of CBD products. Well, not so much although this week, the US House did pass a bill that would allow US troops to use CBD products. This is some movement, even if dialogue between industry and FDA has languished and FDA itself does not appear to have made much of an advance in its thinking about how to effectively regulate CBD products. CBD largely though has been bumped from the news for the better part of 2020. In our ‘what’s not’, we said we did not expect to see industry-led new science. Guess we got that one right, although it’s so tough to actually do the research in the current gray zone of official regulation.

Back to our projected ‘What’s hots, we predicted further definition and stratification in the plant-based market. It’s a pretty ambiguous prediction, arguably being delivered, or certainly well on its way. Our next big prediction was more transparency and pressure on disclosure of synthetic ingredients; as it turns out, if our recent survey is any indication, we missed on that one too. Our next ‘what’s hot’ prediction was rather hopeful and is closely tied to what we hoped was not going to happen. It had to do with the 2020 debate on nutrition science and the US dietary guidelines. We hoped we would see a rethinking and refreshing use of emerging science along a continuum that gradually expands knowledge in the space. Instead, and this was vocally called out by process critics, the committee retrenched itself in debunked science and really did not take solid steps forward in crafting the healthful and practical guidelines many had hoped for. So we still have bad science influencing bad food policy.

The other elements we were looking for as we gazed into 2020 were more behavioral and here reader, you’ll have to help us out. We were looking for more category-based collaboration (things like category-based research and messaging), more supply chain transparency like disclosure of country of origin, contract manufacturers and contract labs, and ever-increasing authenticity. Maybe I’m just a tad jaded, but I’m not sure we’ve seen those last three increase appreciably. The first, ‘collaboration’, was also reflected in our ‘what’s not’ – isolation.

There were several areas that we thought had crested or were hoping to see active steps to eliminate certain behaviors. The current crisis has created new opportunities for ‘fairy dusting’ of ingredients and outright adulteration as the predictable experience of elderberry suppliers proves. If popularity of an ingredient can be exploited, bottom feeders in our industry will do so.

All in all, we didn’t totally miss the mark for the year, and have probably teased out a few long plays. Obviously, we missed the current crisis, the buoying of immunity products and the resulting health halo benefit across much of the supplement universe. We’ll also double-down on personalization now, not the n=1 diagnostic-based kits that technology can now provide, but a really deep dive into “what do I need, for me and mine, right now, my most important decision, because I need to make these decisions, matter more than ever.”

Another observation of note, confirmed with many industry contacts – for the past 6 months, true product ‘de novo’ innovation has often been placed on hold. It was ‘triage’ for many companies to keep supply chains operating and warehouses as full as possible. We did see ingredients added to formulations to support brand extensions, but few new ingredient suppliers qualified for true new product development and release. We’re now into the ‘what’s new’ period, and the next 6 months and into 2021will produce true new products. That’s not to say that supply chain rethinking and repatriation won’t occur, it’s that new product development will be done with a mind to risk limiting the supply chain.

We get a mixed mark so far this year, how about you?

Unlock the Power of Transparency: Schedule a Meeting Now

Ready to Illuminate Your Path?
Partner with Trust Transparency Today.

Get inTouch

Lori Diez

Lori Diez combines compassion and excellence to lead organizations to their next level. A small-town Texas childhood taught her the value of hard work and relationships, which she uses to foster teamwork that brings results that have transformed cultures and programs to their highest potential. Her successful career in pharmaceutical and nutraceutical sales leadership and event hosting has prepared her to deliver results as the COO of TrustTransparency, where she uses her industry knowledge to ensure that the company’s operations run smoothly as they support nutraceutical companies in their mission to help others. Lori’s passion for charity reflects her belief that individuals working together can change the world, no matter how small their contribution to the effort. This year, she looks forward to continuing over a decade of service at the Houston Livestock Show And Rodeo, where she will be the Chairman of the Livestock Committee.

Conference Handouts

Conference Handouts

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 Case Study

CoQ10 Statin Associated Myaglia Meta Study Barry Tan 0618 (1)

Statin Q10 Effect Case Study

Statin Q10 Effect Case Study

Schedule Consultation with Trust Transparency

Glynnda Steinford

Glynnda Steinford, Trust Transparency Consulting’s Director of Customer Relations, brings over four decades of healthcare experience to her vital role in client engagement and relationship building. Her diverse background spans from administering medical groups to impactful stints in pharmaceutical and nutraceutical sales, all underlined by her degree in Healthcare Administration.

At the heart of Glynnda’s work is her talent for nurturing long-term connections, a skill she leverages to enhance client experiences and partnerships within the consultancy. Beyond her professional commitments, she enjoys life’s simple pleasures, whether it’s her love for cats and cooking or her ventures into golf, always prioritizing cherished moments with family and friends. Her personal interests echo the dedication and warmth she extends in her professional network, making her an invaluable asset to the team.

Caiti Dowden

Caiti Dowden stands as a crucial pillar at Trust Transparency Consulting, bringing invaluable insight and expertise to her role as Senior Executive Assistant’ since her start in 2018. With an academic background from Sam Houston University and a career shift from education to the nutraceutical sphere in 2010, Caiti has cultivated a sharp acumen for dissecting industry trends and bolstering strategic decision-making.

Her transition from Data Analyst reflects her growth and deep understanding of the business landscape. Caiti’s commitment goes beyond professional excellence; she thrives on balance, drawing from her rich life outside of work to enhance her organizational contributions. Whether it’s family time, volunteering, or rooting for Houston’s sports teams, she believes in embracing experiences to fuel her professional creativity and insight.

In her current role, Caiti’s dedication to dynamic business analysis and operational support proves her to be an irreplaceable asset to our team, embodying the synergy of personal enrichment and professional success.

Pam Hilpert

Pam Hilpert, Chief of Staff at Trust Transparency Consulting, has been instrumental in the firm since its inception, leveraging her 17 years of accounting experience, including a significant tenure in the nutrition sector. Her collaboration with Scott Steinford spans various successful ventures, emphasizing her integral role in the company’s financial and strategic initiatives.

An alumnus of Sam Houston State University, Pam holds degrees in both Business Administration and Accounting, as well as an MBA, adding academic heft to her practical industry insights. Beyond her professional prowess, Pam is passionate about family, enjoys live music, delves into quilting, and volunteers at her church, reflecting her well-rounded life.

Her multifaceted expertise and longstanding dedication make Pam a cornerstone of Trust Transparency Consulting’s operational strength and team unity.

Scott Steinford

Scott Steinford, a trailblazer in strategic leadership, boasts a certified M&A background, having navigated companies from their genesis to industry prominence. His brainchild, Trust Transparency Consulting, born in 2007, stands as a testament to his dedication to ethical business practices and strategic foresight, offering industry stakeholders invaluable guidance.

Beyond founding and steering companies, Scott has enriched the business landscape with his insightful keynotes and prolific written contributions, emphasizing his commitment to elevating industry standards. His executive tenure shines in roles as CEO or President of for-profits like ZMC-USA and Doctor’s Best, extending to significant contributions in non-profit sectors.

Notably, Scott’s influence is a driving force in the CoQ10 market, where his leadership has significantly bolstered the ingredient’s global presence. His roles in various capacities, including as a New Hope Ambassador, keep the community informed, providing in-depth industry reports and insights.

An active advocate within professional associations and an Editorial Advisor for leading industry publications, Scott’s expertise is both recognized and sought after. With academic roots in Pre-Law and a Master’s in Law, his journey transcends textbooks, embodying real-world business acumen and transformative leadership.

Scott Steinford merges visionary entrepreneurship with principled leadership, creating a legacy of innovation, growth, and unwavering commitment to industry excellence.